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ess: tsushima@hsp.md.Summary This study was to examine the clinical differences between Stage 0 and
normal subjects, using low-dose chest computed tomography (CT) and pulmonary
function tests. Enrolled subjects performed as a health check for lung cancer
screening including low-dose CT and pulmonary function tests. Subjects were divided
into Stage 0, chronic obstructive pulmonary disease according to pulmonary function
tests, and normal subjects. The severity of emphysema (visual score) was calculated
on three low-dose CT slices. Low-dose CT and pulmonary function tests were
performed in 1359 men and 888 women. The numbers and percentages of men and
women smokers were 1076 (79.2%), and 107 (12.0%), respectively. A total of 722
individuals had one or more respiratory symptoms, such as cough (69.8%), sputum
(75.8%), or shortness of breathing (0.83%). Of the 722 subjects, 71 (9.8%) individuals
satisfied the criteria of chronic respiratory symptoms. Among the normal subjects,
smoking caused differences in airflow limitation as a result of pulmonary function
tests. The proportion of smokers and the visual score were significantly higher in Stage
0 than those in the normal subjects. The percentages of the maximal mid-expiratory
flow (%MMF) and of the peak expiratory flow rate were significantly lower in Stage 0
than in the normal subjects. %MMF and the proportion of visual score were significantly
lower in the smoking Stage 0 than in the nonsmoking Stage 0 subjects. Smoking would
indicate early signs of emphysematous change between Stage 0 and normal subjects in
comparison of pulmonary function tests and visual score of low-dose CT.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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The differences of Stage 0 subjects 1361effective intervention is to stop smoking, prefer-Introduction
Chronic obstructive pulmonary disease (COPD) has
been forecast to be the third leading cause of death
in the world by 2020 because of the global increase
in smoking.1 Recently, a Japanese epidemiological
study indicated that over 5,300,000 Japanese
people (approximately 8.5% of the total popula-
tion) may suffer from COPD.2 However, the number
of patients receiving treatment for COPD was only
approximately 210,000. Many people who develop
COPD are smokers, and their pulmonary function
decreases more rapidly than that of nonsmokers.3,4
COPD is normally diagnosed by pulmonary function
tests, which are often used for the initial diagnosis
and assessment of severity of emphysema. How-
ever, COPD is an insidious disease, with many years
intervening between the development of pulmon-
ary dysfunction and the onset of serious respiratory
symptoms, such as severe breathlessness.
Many studies have indicated that smoking is the
major environmental factor contributing to the
decrease in pulmonary function. Passive exposure
to cigarette smoke may also contribute to respira-
tory symptoms and COPD by increasing the lung’s
total burden of inhaled particulates and gases.5
Cessation of cigarette smoking does not necessarily
result in the recovery of the level of pulmonary
function but it is associated with slower rates of
decline in pulmonary function.6,7 Moreover, cessa-
tion of cigarette smoking can improve the survival
prospects of middle-aged smokers over the entire
range of pulmonary function.8 Smoking reduction
meaning a reduction in the number of cigarettes
smoked per day; however, this is associated with a
small increase in risk as compared with sustained
heavy smokers.9
Cigarette smoke has direct toxic effects on
bronchial epithelial cells and alveoli, and the
pathological changes include mucus hypersecre-
tion, ciliary dysfunction and airflow limitation.
Mucus hypersecretion and ciliary dysfunction are
related to chronic cough and sputum production.
These symptoms are often present for many years
before the development of other more serious
symptoms (shortness of breath, dyspnea) or patho-
logical abnormalities. The classification of severity
based on the Global Initiative for Chronic Obstruc-
tive Lung Disease (GOLD) includes Stage 0, which
includes subjects at risk of developing COPD late in
life.10 Subjects in the Stage 0 group complain of
chronic cough and sputum production but have no
airflow obstruction, as defined by a decrease in
forced expiratory volume in 1 s (FEV1). Active
smoking is strongly associated with chronic cough
and sputum production. Therefore, the mostably at an early stage, such as of Stage 0.3
Screening the general population for the respira-
tory symptoms of Stage 0 is effective but not
feasible in the daily routine of a general practice.
However, Stage 0 includes patients with other
respiratory diseases, such as bronchial asthma,
chronic bronchitis, etc. As a result, many indivi-
duals who have other underlying diseases are
included in Stage 0. It is necessary to promote the
cessation of smoking as a means of early interven-
tion in Stage 0 subjects. The present study was
performed to examine the clinical differences
between Stage 0 subjects, i.e., those defined as
‘‘at risk’’ of COPD and normal subjects, using
clinical information, low-dose chest computed
tomography (CT) scan and pulmonary function
tests.Materials and methods
Our research protocol, including the use of low-
dose CT and pulmonary function tests, was ap-
proved by the human ethics committee of Azumi
General Hospital.
Subjects
During our health-screening program for the detec-
tion of lung cancer (February 1, 2003, to January
31, 2004), enrolled individuals, who participated
after lung cancer screening was publicized in our
community, received a general health check in-
cluding a low-dose chest CT scan and pulmonary
function tests. They were also representative of
the general population in that they included a
highly motivated group of individuals who had some
reason to worry about lung cancer. The enrolled
individuals were from the general population of the
Azumi or Kouhoku area around Azumi General
Hospital, or belonged to an agricultural cooperative
association in Nagano Prefecture. There were no
selection criteria such as age, smoking history,
occupation or symptoms. Low-dose chest CT scan
was performed to detect lung cancer. All indivi-
duals gave their informed consent at presentation
for chest CT scan and pulmonary function tests.
They first underwent a low-dose chest CT and
pulmonary function tests were performed. The
subjects filled out a questionnaire about lifestyle,
respiratory symptoms, smoking history, past his-
tories and demographic data as of the health-
screening program. The information was entered
into a database. Questions about respiratory
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K. Tsushima et al.1362symptoms were related to cough, sputum and
shortness of breath. All of the questions had been
validated previously. Questions and ratings of
responses related to the above symptoms included:
(1) frequency of these symptoms (none, intermit-
tently, almost every day), (2) duration (within 1
week, within 1 month and over 3 months) and onset
of these symptoms, (3) progressive or persistent
symptoms. We excluded subjects with self-
reported asthma, bronchiectasis, diffuse pan-
bronchiolitis or pulmonary tuberculosis with
severe obstructive pulmonary function on the basis
of the clinical information, including past history
and medical history, chest CT findings and self-
report.Pulmonary function tests
Pulmonary function tests were performed using our
routine method.11 All subjects performed spirome-
try within 15–45min after inhaling a b2 stimulant.
The vital capacity (VC), forced vital capacity (FVC),
maximal mid-expiratory flow (MMF) and FEV1 were
measured by Spiroshift SP-700 (Fukuda Denshi,
Tokyo). The %MMF was calculated, and the peak
expiratory flow rate (PEFR) and flow rate at 50%
and 25% of the FVC (V 050, V
0
25, respectively) were
calculated from the maximum expiratory flow–vo-
lume curve. Furthermore, we also calculated
V 050=V
0
25 and V
0
25/height (V
0
25/HT). VC, FEV1 and
PEFR were expressed as percentages of the
predicted values (VC% predicted, FEV1% predicted,
and %PEFR, respectively) according to the predic-
tion equations of the Japanese Society of Chest
Diseases.COPD criteria
The diagnosis of COPD was based on clinical
symptoms and the results of spirometry according
the criteria of the GOLD.10 The severity of COPD
was categorized according to GOLD. Five different
stages were defined as follows: Stage 0 ¼ ‘‘at risk’’
(presence of chronic cough and sputum production,
FEV1/FVCX70% and FEV1X80% predicted), Stage I,
II, III, and IV. Those individuals reporting respiratory
symptoms (intermittently/almost every day, and
with a duration of over 3 months) were included in
the Stage 0 group. The individuals whose symptoms
of cough and sputum subsided within 1 month were
classified as normal subjects. The individuals with
shortness of breath were classified in the Stage 0 or
COPD group.Multislice CT
Each participant underwent a low-dose Multislice
CT scan (Toshiba Asteion Multi, Tokyo, Japan)
(25mA, 120 kVp, 5-mm section thickness, 8-mm
slice thickness of the reconstructions, 0.75 s of
rotation, 10mm/s table speed, and pitch of 5.5). All
CT images were viewed in cine-mode format on a
computer workstation by one radiologist (S.S.) and
pulmonologist (K.T.) with 40 and 11 years of
experience, respectively. The severity of emphyse-
ma was scored subjectively using the scoring
method of Goddard on three 5-mm slices obtained
at full inspiration.12 Emphysematous destruction
was identified as areas of low attenuation and
hypovascular regions in the lung.13 The percentage
of the lung with emphysematous changes was
determined using the following five-point scale:
visual score 0, o5%; 1, 5%p% low attenuation area
(%LAA)o25% involvement; 2, 25%p%LAAo50%; 3,
50%p%LAAo75%; and 4,X75%. The maximum value
was 24. A positive visual score was defined as any
visual score greater than 0. The type of emphysema
on chest CT findings at the three selected slices was
classified as centrilobular emphysema showing
mainly centrilobular emphysematous changes
(CLE), paraseptal emphysema showing mainly sub-
pleural emphysematous changes excluding bulla and
bleb (PSE), panlobular emphysema showing mainly
panacinar emphysematous changes (PLE), and com-
binations of the three types (mixed type).
Statistical analysis
We assessed the difference in sex, age, smoking
history, visual score and pulmonary function vari-
ables between Stage 0 subjects. Data for contin-
uous variables are shown as mean7SD. We used
Student’s t-test to assess the differences between
two groups and to test for differences in visual
score and pulmonary function variables between
Stage 0 and nonStage 0 subjects. Pearson’s w2-test
was performed to test for differences in the
distribution of these categorical variables among
each group. A stepwise method was used to test for
differences in variables to adjust for multiple
comparisons (SAS JMP version 5.1, SAS Institute
Inc. Cary, NC). We considered P-values of less than
0.05 to be significant.Results
As shown in Table 1, 1358 men and 888 women
underwent low-dose chest CT scans and pulmonary
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February 1, 2003, through January 31, 2004. The
subjects’ mean age was 53.7712.7 years. The
numbers and percentages of male and female
smokers were 1076 (79.2%), and 107 (12.0%),
respectively. The numbers of never-, ex-, and
present smokers were 1063, 453, and 730, respec-
tively. The mean numbers of pack-years of ex- and
present smokers were 22.7 and 30.7, respectively.
Forty-eight (2.1%) of 2247 individuals (men, 40;
women, 8; present smokers, 27; ex-smokers, 14;
nonsmokers, 7) were diagnosed with Stage I to
Stage III COPD. A total of 722 individuals had one or
more respiratory symptoms, such as cough (69.8%),
sputum (75.8%), or shortness of breathing (0.83%).
Of the 722 subjects, 71 (9.8%) complained of
chronic productive cough and sputum. They satis-
fied the criteria for GOLD Stage 0. There was a
lower prevalence of women among both Stage 0
and normal subjects. There was a significantly
higher proportion of smokers among the Stage 0
subjects than among the normal subjectsTable 1 Characteristics and data of individuals with ‘‘N
(A) Normal
(n ¼ 2127)
Age (years) 53.379.7
Sex, M/F 1262/865
Smoking history
No. of subjects (%) 1090 (51.2%)
Current-smokers (%) 659 (31.0%)
Pack-years 29.5716.5
Ex-smokers (%) 431 (20.3%)
Pack-years 22.1718.1
Never-smokers (%) 1037 (48.8%)
Symptoms—no. of subjects (%)
Cough (no) 433 (20.4%)
Sputum (no) 476 (22.4%)
Pulmonary function data
VC (L) 3.6470.87
VC% predicted (%) 113715
FEV1 (L) 2.9770.73
FVC (L) 3.5870.85
FEV1/FVC (%) 84.275.4
FEV1% predicted (%) 111716.2
V 025/HT (L/s/m) 0.9070.43
V 050=V
0
25 3.1171.0
%MMF (%) 97.7729
%PEFR (%) 106723
Low-dose chest CT
Positive visual score—no. of subjects 203 (9.5%)
Data of continuous variables expressed as mean7SD and diffe
Categorical data (sex, smoking history—number of subject, sym
number; COPD, chronic obstructive pulmonary disease; VC, vita
expiratory flow; FEV1, forced expiratory volume in 1 s; PEFR, peak
the forced vital capacity; V 025/HT, V
0
25/height.(Po0:0001). The %MMF and %PEFR were signifi-
cantly lower in Stage 0 than in normal subjects. All
the listed variables, excluding %VC, were signifi-
cantly worse in COPD than in Stage 0. Three
patients with bronchiectasis, and six with old
tuberculosis with severe obstructive pulmonary
function were excluded from the study.
The chest CTof the Stage 0 group identified eight
subjects with PSE, nine with CLE and two with the
mixed type (Table 2). The proportion of positive
visual score in the Stage 0 group was significantly
higher than that in normal subjects. Sixteen of the
17 subjects with positive visual score were smokers
in the Stage 0 group. The results of adjustment for
multiple comparisons of each variable are shown in
Tables 1 and 2, and number of pack-years, visual
score and %PEFR showed significant differences
between the groups.
As shown in Table 3, among normal subjects,
cigarette smoking brought to the differences of
airflow obstruction as results of pulmonary function
tests. The proportion of positive visual scoreormal’’, ‘‘Stage 0’’ and ‘‘COPD’’.
(B) Stage 0
(n ¼ 71)
(C) COPD
(n ¼ 48)
P-value (A)
vs (B)
54.5710.7 61.179.3 0.062
56/15 40/8 0.0023
52 (73.2%) 41 (85.4%) 0.0014
44 (62.0%) 27 (56.3%) o0.0001
37.2722.0 38.8717.1 0.0074
8 (11.2%) 14 (29.2%) 0.0475
21.4715.3 40.9718.6 0.061
19 (26.8%) 7 (14.6%) 0.0005
71 (100%) 20 (41.7%) o0.0001
71 (100%) 25 (52.1%) o0.0001
3.7970.98 3.3770.90 0.15
110717 102719 0.046
3.0170.91 1.9870.66 0.46
3.6270.99 3.1070.89 0.48
82.976.2 63.575.5 0.044
105719 77.5719 0.011
0.8770.44 0.3370.17 0.25
2.9270.74 2.8371.6 0.031
89.4732 34.2711 0.019
98.2723 70.3722 0.011
19 (26.8%) 31 (64.6%) 0.0002
rences between groups were analyzed by ANOVA (F-test).
ptoms—cough, and sputum) were analyzed by w2-test. no,
l capacity; FVC, forced vital capacity; MMF, maximal mid-
expiratory flow rate; V 050 and V
0
25, flow rate at 50% and 25% of
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Table 2 Computed tomography findings in ‘‘Normal’’ and ‘‘Stage 0’’ (excluding COPD).
Normal (n ¼ 2127) Stage 0 (n ¼ 71) P-value
Abnormal Finding—no. of subjects (%)
CLE 101 (4.7%) 8 (11.3%) 0.079
PSE 73 (3.4%) 9 (12.7%) 0.032
PLE 2 (0.1%) 0 40.99
Mixed (CLE, PSE, PLE) 27 (1.3%) 2 (1.9%) 0.44
Others 165 (7.8%) 12 (17.4%) 0.0075
Positive visual score—no. of subjects 203 (9.5%) 19 (26.8%) 0.0002
*Data are mean7SD.
CLE, centrilobular emphysema; PSE, paraseptal emphysema; PLE, panlobular emphysema; COPD, chronic obstructive pulmonary
disease; no, number.
Table 3 Comparison among ‘‘Normal nonsmoker’’, ‘‘Normal smoker’’ and ‘‘Stage 0’’ subjects.
(A) Normal
nonsmoker
(n ¼ 1037)
(B) Normal smoker
(n ¼ 1090)
(C) Stage 0
(n ¼ 71)
Age (years) 54.379.6 52.479.8** 54.5710.7
Sex, M/F 271/766 991/99** 56/15**,##
Pack-years 0 26.9717.8 25.1722.8
Pulmonary function data
VC (L) 3.2270.78 4.0370.76** 3.7970.98**,##
VC% predicted (%) 114715.0 112715.2* 110717*
FEV1 (L) 2.6770.66 3.2670.68** 3.0170.91**
,##
FVC (L) 3.1470.75 3.9170.77** 3.6270.99**,##
FEV1/FVC (%) 85.175.2 83.475.3** 82.976.2**
FEV1% predicted (%) 114716.6 108716.4** 105719**
V 025/HT (L/s/m) 0.8870.38 0.9370.47** 0.8770.44
V 050=V
0
25 3.1171.23 3.1070.81 2.9270.74*
,#
%MMF (%) 102727.7 94.0729.8** 89.4732**,#
%PEFR (%) 105.4722.5 105.8723.1 98.2723**,##
Low-dose chest CT
Positive visual score—no. of subjects 41 (4.0%) 160 (14.7%)** 19 (26.8%)**,#
COPD, chronic obstructive pulmonary disease; VC, vital capacity; FVC, forced vital capacity; MMF, maximal mid-expiratory flow;
FEV1, forced expiratory volume in 1 s; PEFR, peak expiratory flow rate; V
0
50 and V
0
25, flow rate at 50% and 25% of the forced vital
capacity; V 025/HT, V
0
25/height; no, number.
* Po0:05 vs (A), **Po0:01 vs (A), #Po0:05 vs (B), ##Po0:01 vs (B).
K. Tsushima et al.1364showed significant differences between normal
nonsmoking and normal smoking subjects. Stage 0
subjects had the development of small airway
disturbances, including V 025/HT, V
0
50=V
0
25 and %MMF
compared with normal smoking subjects.
As shown in Table 4, the %MMF were significantly
lower in the smoking Stage 0 than in nonsmoking
Stage 0 subjects. There was a higher prevalence of
men of smoking Stage 0 than that of nonsmoking
Stage 0 subjects. The proportion of positive visual
score of the smoking Stage 0 subjects was sig-
nificantly higher than that of nonsmoking Stage 0
subjects. In Stage 0 subjects, smoking had effects
on the abnormality of chest CT findings and the
prevalence of men.Discussion
There is little confirmatory data on whether Stage 0
is suitable for identifying the population at risk for
the development of COPD in the general popula-
tion.14 Vestbo et al. indicated that the definition of
Stage 0 enables a better spread of information as to
the disease or facilitates the promotion of smoking
cessation.14 They also reported that chronic mucus
hypersecretion is strongly associated with FEV1
decline as well as subsequent hospitalization for
the treatment of COPD. In subjects classified as
Stage 0, productive cough in the absence of air-
way obstruction does not reflect increased risk,
whereas chronic mucus hypersecretion with airway
ARTICLE IN PRESS
Table 4 Comparison between smoking ‘‘Stage 0’’ and nonsmoking ‘‘Stage 0’’ subjects.
(A) Stage 0 (ex-,
current smokers)
(n ¼ 52)
(B) Stage 0 (never-
smokers) (n ¼ 19)
P-value (A) vs
(B)
Age (years) 53.2711.0 58.279.7 0.18
Sex, M/F 47/5 9/10 o0.0001
Pack-years 34.3719.8 0 —
Pulmonary function data
VC (L) 3.9770.93 3.3170.94 0.007
VC% predicted (%) 111718.0 110714.0 0.42
FEV1 (L) 3.1370.92 2.6870.83 0.046
FVC (L) 3.7770.97 3.2370.96 0.027
FEV1/FVC (%) 82.776.1 83.376.8 0.37
FEV1% predicted (%) 105719.0 111717.6 0.064
V 025/HT (L/s/m) 0.8770.41 0.8770.53 0.83
V 050=V
0
25 2.8770.69 3.0670.88 0.20
%MMF (%) 86.8731.5 96.6730.5 0.05
%PEFR (%) 99.5725.0 94.4717.0 0.19
Low-dose chest CT
Positive visual score—no. of subjects 18 (34.6%) 1 (5.3%) 0.015
COPD, chronic obstructive pulmonary disease; VC, vital capacity; FVC, forced vital capacity; MMF, maximal mid-expiratory flow;
FEV1, forced expiratory volume in 1 s; PEFR, peak expiratory flow rate; V
0
50 and V
0
25, flow rate at 50% and 25% of the forced vital
capacity; V 025/HT, V
0
25/height; no, number.
The differences of Stage 0 subjects 1365obstruction does.15 They reported that among
those ‘‘at risk’’ in the second survey, approximately
half were Stage 0 at baseline and half had
experienced no symptoms. After an additional 10
years, 14% with new Stage 0 COPD and 18% with
stable Stage 0 COPD had developed Stage I COPD.14
These results do not seem to warrant a special
follow-up of Stage 0 subjects to establish whether
the condition is stable. Based on these results,
previous studies concluded that Stage 0 is of little
help in identifying subjects at risk of COPD.14,15
However, there is little information on whether
Stage 0 subjects have other abnormal pulmonary
function data and abnormal chest CT findings prior
to the development of airflow limitations. In the
present cross-sectional study, we examined the
clinical differences of Stage 0 subjects using
clinical information and pulmonary function data
against subjects who were subjected to low-dose
CT as a health check.
The studies of Vestbo et al. indicated that
cigarette smoking itself remains the best predictor
of COPD development.14,15 As shown in Table 1, the
proportions of current smokers and number of
pack-years of the Stage 0 group were significantly
higher than those of normal subjects (Po0:01).
Marco et al. reported that in young adults (o40
years), a considerable percentage of subjects
already suffered from COPD and chronic symp-
toms.16 In the present study, the V 050=V
0
25, %MMF
and %PEFR of the Stage 0 subjects were significantlylower than those of the normal controls. This result
suggested that subjects with chronic respiratory
symptoms already suffer from airflow limitation
due to small airways. The V 050=V
0
25 and %MMF is
associated with the small airway disturbance
induced by cigarette smoking. There are Stage 0
subjects with a history of smoking and abnormal
pulmonary function data showing small airway
disturbances, including the %MMF and %PEFR,
among those classified as Stage 0. However, the
%MMF and %PEFR values of the Stage 0 subjects
were significantly higher than those with COPD,
probably due to the development of pulmonary
damage in the latter group. Jackson et al. reported
that a cut-off %PEFR value of less than 80% allows
the detection of more than 90% of people with
COPD.17 Moreover, cigarette smoking only showed a
significant difference between smoking and non-
smoking Stage 0 subjects based on the results of
multiple comparisons. Therefore, Stage 0 subjects
with abnormal pulmonary function data may
represent a group at higher risk, and thus it is
important to detect the smoking Stage 0 among
Stage 0 and normal subjects.
Chest CT findings can show the emphysematous
changes with reference to smoking history and
FEV1%. Chest CT has been reported to accurately
reflect the histological structure of the lung and to
be useful in the diagnosis and evaluation of various
types of pulmonary parenchymal diseases.10 Sev-
eral studies designed to detect and quantify
ARTICLE IN PRESS
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reported.18,19 The LAA derived from the chest CT
scan is correlated with macroscopic and micro-
scopic emphysematous changes in the lungs.20,21
The severity of emphysema scored subjectively by
Goddard was also correlated with the grade of
COPD.12 However, the presence of abnormal find-
ings on chest CT or chest X-ray was not discussed
previously as a risk factor in Stage 0 subjects for
COPD to keep GOLD guidelines simple to use all
over the world. In the present study, some subjects
without abnormal spirometry results had evidence
of emphysematous changes on chest CT. As demon-
strated in the present study, many subjects with
emphysematous changes were current smokers or
ex-smokers. The proportion of the Stage 0 sub-
jects with a positive visual score was significantly
higher than that in normal subjects. In the normal
subjects, the proportion of positive visual scores
for the normal smoker was significantly higher
that that of the normal nonsmoker subjects. In
the smoking Stage 0 group, the proportion of
positive visual score was significantly higher than
that in the nonsmoking Stage 0 group. In this
study, cigarette smoking is one of the important
factors contributing to the decrease in pulmonary
function. Therefore, smoking Stage 0 subjects
with emphysematous change show apparent
clinical differences as compared with normal
subjects. Individuals identified by the combination
of smoking history, airflow limitation and emphy-
sematous changes on chest CT findings should be
regarded as a different subgroup of Stage 0
subjects.
The most interesting results in this study are
shown in the Tables 3 and 4. The proportion of
positive visual score showed significant differences
between normal nonsmoking and normal smoking
subjects. The proportion of positive visual score of
the smoking Stage 0 subjects was significantly
higher than that of nonsmoking Stage 0 subjects.
In Stage 0 subjects, smoking had effects on the
abnormality of chest CT findings and the preva-
lence of men. Stanescu et al. reported that a
subset of smokers characterized by a low FEV1/FVC
ratio and a high N2 slope are probably the high-risk
subjects with clinically overt COPD.22 In our
present study, as shown in Tables 3 and 4,
asymptomatic smokers had early signs of emphyse-
ma when visual scores and lung function were
compared among normal nonsmokers, normal smo-
kers and Stage 0 subjects. The subjects of this
screening study were individuals under 60 years of
age without any recognized illness. The results of
this study emphasize the need to provide support
clinically and educationally for such smoking Stage0 subjects to prevent further worsening of emphy-
sematous changes.
We did not follow up the subjects over a long
period to determine whether Stage 0 actually
developed to COPD at some time in the future.
These subjects should be followed up to determine
the natural history of COPD, and such studies will
allow proper assessment of the likelihood of
progression of these Stage 0 subjects to more
severe stages. Another limitation was that we could
not exclude the possibility that chronic cough and
sputum were purely expressions of asthma because
of the overlap between COPD and asthma. It was
not possible to achieve a precise diagnosis or
exclude airway hypersensitivity because the infor-
mation was obtained from self-reported question-
naires. On pulmonary function tests, we did not
measure the carbon monoxide diffusing capacity. It
was reported previously that subjects with COPD
have reduced diffusing capacity for carbon mon-
oxide at an early phase.23 However, the test, as
well as the measurement of forced residual
capacity, could not be performed within the limited
time of the general health check.
In conclusion, we were able to indicate that
asymptomatic smokers have early signs of emphy-
sematous change seen in comparison of pulmonary
function tests and the visual score of low-dose
chest CT. It is necessary to promote the cessation of
smoking as a means of early intervention for
smoking subjects.References
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